Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pioneering Yale Immunologist Receives Inaugural NIH Award

Published: Thursday, February 28, 2013
Last Updated: Thursday, February 28, 2013
Bookmark and Share
Renowned Yale immunologist Ruslan Medzhitov has been awarded the inaugural Lurie Prize in the Biomedical Sciences from the Foundation for the National Institutes of Health (FNIH).

The award, which honors early-career researchers whose findings have advanced basic biomedical science, was given to Medzhitov for his groundbreaking discoveries about the workings of the innate immune system, the body’s first line of defense against bacteria and viruses.

A jury of scientists, headed by Dr. Solomon Snyder of Johns Hopkins University, selected Medzhitov from a group of 154 nominees. The award, which carries an honorarium of $100,000, will be presented to Medzhitov at a ceremony on Tuesday, May 14 in Chicago.

Medzhitov, the David W. Wallace Professor of Immunobiology and a Howard Hughes Medical Institute investigator, came to Yale in 1994 as a postdoctoral fellow in the lab of Charles Janeway. The two researchers made the groundbreaking discovery that a human toll-like receptor (TLR), a component of the innate system, provides the adaptive system with the necessary information to create custom-made B and T cells that target specific bacterial or viral invaders, through recognition of basic molecular patterns shared by microbial pathogens. Since then, toll-like receptors have become the subject of intense research activity in laboratories around the world.

“Dr. Medzhitov’s painstaking studies paved the way for the identification of multiple TLR family members and their respective ligands, which help bind molecules forming larger complexes, advancing the entire field of immunology and opening the way for the development of new vaccines and treatments,” Snyder said. “He is a true pioneer of medical science.”

The Lurie Prize is the first of its kind to specifically recognize young scientists – under the age of 52 – who have changed the field of biomedical research. It was established by philanthropist Ann Lurie and reflects her passion for advancing biomedical research and medical care. “My specific interest is to reward and acknowledge a scientist who makes a discovery that is clearly a game changer in terms of medical and biological research,” said Lurie.

“This is award is a tremendous honor, and I am very grateful to all my colleagues, teachers and trainees,” Medzhitov said. “I am especially grateful to the FNIH and its scientific jury for recognizing the tremendous progress in the field of innate immunity to which so many of my colleagues have contributed.”

Medzhitov was nominated for the Lurie award by his Yale colleague Richard Flavell, Sterling Professor of Immunobiology, chairman of the department, and also a Howard Hughes Medical Institute investigator.

Medzhitov, a member of Yale Cancer Center, was one of three scientists awarded the prestigious Shaw Prize in Life Science and Medicine for 2011. In April, 2010, he received one of the highest honors bestowed on American scientists when he was elected to the National Academy of Sciences, the elite corps of researchers from the nation’s top scientific institutions.

In December, 2009, Medzhitov won the 2010 Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Science for his “elucidation of the mechanisms of innate immunity,” according to the Rosenstiel Center. Medzhitov’s studies helped shed light on the critical role of toll-like receptors in sensing microbial infections, mechanisms of TLR signaling, and activation of the inflammatory and immune response.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
Tuesday, April 12, 2016
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
Wednesday, July 08, 2015
Racial and Economic Gap in Awareness of Lifesaving HPV Vaccine
Research finds worrisome racial, economic, educational, and gender gaps in awareness about the lifesaving vaccine for HPV.
Monday, June 10, 2013
Yale Researchers Trick Bacteria to Deliver a Safer Vaccine
Yale researchers have developed a new trick, using bacteria’s own cellular mistakes to deliver a safe vaccine.
Tuesday, March 19, 2013
For Drug Makers, New 3-D Control Opens Wealth of Options
Scientists have demonstrated a new, highly versatile approach for quickly assembling drug-like compounds, establishing a broad new route to drug discovery and medical treatment.
Monday, February 18, 2013
Yale Researcher Says Whooping Cough Vaccines Effective, Despite Outbreaks
Dr. Shapiro’s editorial was published in the Nov. 28 issue of Journal of the American Medical Association.
Friday, November 30, 2012
Yale Scientists Find a Way to Make Disease-Causing Proteins Vulnerable to Drugs
Researchers have identified a novel way to design drugs for previously inaccessible proteins.
Friday, July 27, 2012
Scientific News
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!